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O presente trabalho reporta um estudo teórico e experimental detalhado das séries inéditas 
de isômeros cis- e trans-N,N-dimetilcarbamatos de cicloexila 2-arilaminossubstituídos como 
potenciais inibidores de colinesterases. Os testes de inibição in vitro, realizados através do método 
de Ellman em amostras de sangue humano, mostraram que os novos carbamatos apresentaram 
boa seletividade frente à inibição da enzima butirilcolinesterase (BuChE), com um máximo de 
inibição de 90% e IC50 de 6 e 8 mmol L-1 para os compostos mais ativos da série. Os estudos de 
modelagem molecular apontaram significantes diferenças entre as orientações destes compostos 
nos sítios ativos das enzimas BuChE e acetilcolinesterase (AChE). Os resultados mostraram que 
os compostos interagem de forma mais efetiva com o sítio ativo da enzima BuChE, pois o grupo 
carbamato está próximo aos resíduos chave da tríade catalítica.
This work reports a detailed theoretical and experimental study of the novel isomer series 
cis- and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates as potential inhibitors of 
cholinesterases. In vitro inhibition assay by Ellman’s method with human blood samples showed 
that the new carbamates are selective to the inhibition of enzyme butyrylcholinesterase (BuChE) 
with maximum inhibition of 90% and IC50 of 6 and 8 mmol L-1 for the more actives compounds 
of the series. Molecular modeling studies point to significant differences for the conformations 
of the compounds in the active sites of enzymes BuChE and acetylcholinesterase (AChE). The 
results show that the compounds interact more effectively with the active site of enzyme BuChE 
since the carbamate group is close to the key residues of the catalytic triad.
Keywords: carbamate derivatives, cholinesterase inhibitors, molecular docking, Alzheimer’s 
disease
Introduction
Alzheimer’s disease (AD) is a neurodegenerative 
disease characterized by progressive loss of memory and 
other functions. It was first described by Alois Alzheimer 
in 1906.1 This type of mental deterioration is the most 
common in individuals aged over 60 and its incidence 
has increased as the world population has grown older. 
Currently, it is estimated that 26 million people suffer from 
AD in the world.2
Despite the numerous studies done, the causes of 
AD are not fully elucidated and no cure has been found 
yet. Nevertheless, its damages and progression can be 
minimized. The most efficient therapy for the symptomatic 
treatment of AD is based on the cholinergic hypothesis 
in which the cognitive deficiency is a consequence of an 
acetylcholine (ACh) deficiency with a resulting decrease 
in cholinergic neurotransmission.3-6
In physiological conditions, the activity of 
neurotransmitter ACh is known to be related mainly 
to acetylcholinesterase (AChE). However, substantive 
evidence points to the importance of the function of 
Bagatin et al. 1799Vol. 24, No. 11, 2013
butyrylcholinesterase (BuChE) in the cholinergic system.7-10 
Recent studies have shown that due to a progressive 
decrease in the AChE activity in certain regions of the 
brain in AD,4,11 the BuChE activity increases, suggesting 
that BuChE may act as a compensatory mechanism in the 
hydrolysis of ACh.12,13
Due to the cholinergic hypothesis and numerous 
reports on the multiple functions of cholinesterases on the 
pathogenesis and evolution of AD, AChE and BuChE are 
interesting targets for the development of new anti-AD 
drugs.14-19
The action of carbamates as cholinesterase inhibitors 
has been known for decades and several studies have been 
conducted in search of anticholinesterastic carbamates that 
are active, also safe and better tolerated.20-24 Rivastigmine, 
a drug from the carbamate class, is one of four drugs that 
act as cholinesterase inhibitors currently approved by 
ANVISA, the Brazilian Health Surveillance Agency, for 
the treatment of AD.
This study describes the synthesis and evaluation of the 
in vitro activity of two novel series of potential cholinesterase 
inhibitors (Figure 1). Computational calculations were 
performed to determine the conformational preference 
of the isomers and molecular docking was performed 
for the proposal of a binding model for the compounds 
synthesized to the active site of enzymes AChE and BuChE. 
We hope this study may contribute to increase the number 
of therapeutic agents against AD.
Results and Discussion
Synthesis
New cis- and trans-carbamate derivatives were 
synthesized via the route outlined in Scheme 1. trans 
Carbamates were synthesized in two steps. First, 
cyclohexene oxide was submitted to aminolysis with 
arylamines25 to obtain trans-2-arylaminocyclohexanols 
1a-1c with yields from 50 to 80%. Next, the alcohols 1a-1c 
were carbamoylated26 with dimethylcarbamoyl chloride to 
give carbamates 2a-2c with yields ranging from 35 to 50%.
The cyclohexene oxide aminolysis was performed 
without a catalyst and with water as a solvent. Bonollo et al.25 
demonstrated that the reaction efficiency depends on a 
rigorous pH control. The ideal reactional condition is 
attained when 1.0 mmol cyclohexene oxide is mixed with 
1.05 mmol amine in 2.0 mL deionized water; the resulting 
pH of 8.30 varies little during the reaction.
The trans-2-arylaminocyclohexanols 1a-1c were 
carbamoylated with metallic sodium for the preparation 
of the corresponding alkoxide and later reacted with 
dimethylcarbamoyl chloride. However, the joint analysis 
of the nuclear magnetic resonance (NMR) and gas 
chromatography-mass spectrometry (GC-MS) data in 
the preparation of derivative 2c showed the formation 
of a mixture of compounds, 25% of the defluorinated 
compound 2a and 75% of the desired product 2c. Attempts 
to separate these compounds by column chromatography 
were unsuccessful. As an alternative, metallic sodium 
was substituted with sodium hydride in the synthesis of 
compound 2c, which was obtained as a single product. 
The mechanism for hydrodefluorination was reported 
previously27,28 as a sequence of steps, beginning with the 
electron transfer from metal to the substrate and ending with 
the formation of the hydrodefluorination product. Therefore, 
the product 2c was successfully obtained when the metallic 
sodium was substituted by sodium hydride since in this case 
it is not possible the occurrence of electron transfer.
The cis carbamates were synthesized in four steps. 
First, cyclohexanone was reacted with bromide to produce 
2-bromocyclohexanone29 with a yield of 70%. Next, 
racemic 2-arylaminocyclohexanones 3a-3c were prepared 
with 30% yield by substitution of 2-bromocyclohexanone 
with appropriate arylamines,30 using quinoline as a 
catalyst and ethoxyethanol as a solvent. In the third 
step, ketones 3a-3c were stereoselectively reduced in 
the presence of N-selectride,31 giving the respective 
cis-2-arylaminocyclohexanols 4a-4c in moderate yields, 
36-50%. Temperature control (-78 oC) was very important 
in this step to ensure that only the cis isomer was obtained. 
Finally, compounds 4a-4c were carbamoylated26 under 
the same conditions used in the synthesis of the trans 
carbamates to obtain compounds 5a-5c.
Biological activity
Inhibitory potencies of the novel synthesized carbamates 
against cholinesterases from fresh human blood were 
evaluated by Ellman’s modified spectroscopic method.32 
This test is based on the reaction of 5,5’-dithiobis-
(2-nitrobenzoic acid), known as DTNB or as Ellman’s 
reagent, with the sulfhydryl group of acetylthiocholine 
Figure 1. Structures of the two novel series of carbamate derivatives 
cis- and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates.
Molecular Modeling and Anticholinesterasic Activity of Novel 2-Arylaminocyclohexyl N,N-Dimethylcarbamates J. Braz. Chem. Soc.1800
or butyrylthiocholine, which results in the formation of a 
yellow-colored product, 2-nitro-5-thiobenzoic acid (TNB). 
This product has maximum absorbance at 412 nm, thus the 
lower the measured absorbance, the greater the activity 
of the compounds tested, since the enzyme is inhibited. 
Since this method requires water soluble compounds, 
chlorohydrates 2a’-2c’ and 5a’-5c’ were prepared.
The assays were performed at five concentrations 
(0.01, 0.025, 0.05, 0.1 and 0.2 mol L-1) of the potential 
inhibitors. Exelon®, a drug that contains the active 
principle rivastigmine, was used as a standard. In these 
experiments, the inhibition potential of each compound 
against butyrylcholinesterase (found in plasma) and 
acetylcholinesterase (found in red blood cells) was 
assessed.
The inhibition results are shown in Figure 2a-2d. The 
IC50 (the testing compound concentration that inhibits 
the hydrolysis of substrates by 50%) values (Table 1) of 
each compound were obtained through the plot of percent 
inhibition versus compound concentration.
The analysis of Figure 2 shows that all compounds 
were more active in the butirylcholinesterase inhibition 
for any evaluated concentration (Figures 2a and 2c). 
The cis and trans salts produced maximum activity 
inhibition for BuChE, around 90% at 0.2 mol L-1. 
Compounds 5a’ and 2b’ were the most active, with IC50 
values of 6.0 and 8.0 mmol L-1, respectively.
Relative to the acetylcholinesterase inhibition 
(Figures 2b and 2d), compounds 2a’-2c’ and 5b’-5c’ 
followed the same tendency and did not inhibit 50% of the 
enzyme activity in any of the investigated concentrations. 
Only compound 5a’ inhibited AChE significantly, with a 
maximum inhibition of 79% at 0.2 mol L-1.
Likewise, the investigated compounds had good 
selectivity in relation to the BuChE inhibition. Derivative 2b’ 
was the most active selective compound, with an IC50 of 
8.0 mmol L-1. Among the tested compounds, only derivative 
5a’ was active against both enzymes, with an IC50 of 
6.0 mmol L-1 against plasma cholinesterase (BuChE) and 
59.2 mmol L-1 against erythrocyte cholinesterase (AChE).
The analysis of the data shows that the cis-trans 
isomerism does not influence the activity of the compounds 
significantly. However, the presence of donor or acceptor 
substituents in the para position of the aromatic ring may 
Scheme 1. Synthesis route for isomers cis and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates. Reagents and conditions: (a) arylamine, H2O, 60 oC, 
48 h; (b) Nao/THF, 80 oC, 8 h; N,N-dimethylcarbamoyl chloride, reflux, 16 h; (c) NaH/THF, 80 oC, 8 h; N,N-dimethylcarbamoyl chloride, reflux, 16 h; 
(d) Br2, H2O, 0-5 oC; (e) Na2CO3, quinoline, methoxyethanol, reflux, 2 h; and (f) N-selectride, THF, -78 oC, 4 h.
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either increase or decrease the activity of the compounds, 
depending on the series that is analyzed. For the trans series 
(compounds 2a’-2c’), the presence of the methoxyl group 
in 2b’ potentialized the anticholinesterasic activity and was 
approximately two times more active than derivative 2a’. 
For the cis series, the presence of activator (5b’) and 
deactivator (5c’) substituents in the aromatic ring 
significantly reduced the activity of the compounds in 
relation to the non-substituted derivative 5a’.
Bocca et al.23 studied the inhibitory properties of 
2-N,N-dimethylaminecyclohexyl 1-N’,N’-dimethyl-
carbamate isomers and their methyl sulfate salts, and found 
an IC50 of 59 mmol L-1 for the most active compound of the 
series against BuChE. Comparatively, all compounds tested 
in this work (2a’-2c’ and 5a’-5c’) were more active against 
BuChE, with IC50 values ranging from 6 to 29.8 mmol L-1. 
These data demonstrate that the presence of the arylamine 
group potentialized the activity of these carbamates in the 
inhibition of plasma cholinesterase. 
Conformational equilibrium analysis
The molecular modeling calculations were performed 
with Gaussian 03 package programs.33 To investigate 
the cis and trans isomer preferential conformations and 
the influence of the substituents on the conformational 
equilibrium, surface energy potential calculations were 
performed at HF/6-31G level. The most stable structures 
were then optimized at B3LYP/6-311++G(d,p) level, and 
the obtained energy values were used to determine the 
contribution of each conformer to the equilibrium. Table 2 
shows the relative energies and calculated populations of 
each conformer of the studied compounds. Figure 3 presents 
the optimized structure for the cis and trans carbamate 
derivates of aniline (2a and 5a). Similar conformations 
were obtained for the other compounds. 
According to Table 2, all trans isomers presented ee 
as major conformers. This preference can be attributed to 
Figure 2. Concentration effects (0.01, 0.025, 0.05, 0.1 and 0.2 mol L-1) of 2a’-2c’ and 5a’-5c’ on the BuChE (a and c) and AChE (b and d) activities from 
fresh human blood.
Table 1. IC50 values of carbamate chlorohydrates and reference compound, 
rivastigmine, as inhibitors of cholinesterases
Compound BuChE IC50
a
 / 
(mmol L-1)
AChE IC50a / 
(mmol L-1)
2a’ 17.9 n.a.
2b’ 8.0 n.a.
2c’ 29.8 n.a.
5a’ 6.0 59.2
5b’ 17.0 n.a.
5c’ 17.2 n.a.
Rivastigmine 0.031 1.29
aIC50 values are representative of three independent experiments performed 
in triplicate, standard deviations within 10% of mean values reported for 
each compound. n.a.: not active (IC50 > 100 mmol L-1).
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Table 2. Relative energy (Erel) and population for conformers of isomers cis- and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates
trans cis
Compound ee / %
Erel / (kcal mol-1) Compound ae / %
Erel / (kcal mol-1)
ee aa ae1 ae2 ea1 ea2
2a 98.6 0 2.52 5a 90.1 0 0.19 1.13 1.90
2b 97.2 0 2.10 5b 90.2 0 0.27 1.17 1.94
2c 98.2 0 2.37 5c 87.6 0 0.03 0.86 1.89
Figure 3. Structures optimized at B3LYP/6-311++G(d,p) for trans- and cis-2-arylaminocyclohexyl N,N-dimethylcarbamates.
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steric repulsion between the individual substituents and 
the hydrogens in 1 and 3 arrangements (syn, 1,3-diaxial 
interactions). When the substituents adopted equatorial 
positions (ee), these repulsions were avoided and otherwise, 
when the substituents adopted axial positions (aa), these 
interactions were maximized.
These results agree with the coupling constant values 
3JHH obtained from the 1H NMR spectra, with 3JHH greater 
than 9.3 Hz for hydrogens H-1 and H-2, indicating that they 
are in axial position and the substituents (carbamate and 
arylamine) in equatorial position.
For isomers cis-2-arylaminocyclohexyl N,N-dimethyl-
carbamates, two conformations are possible, one with the 
carbamate group in axial position and the arylamine group 
in equatorial position (ae), and another with the carbamate 
group in equatorial position and the arylamine group in 
axial position (ea). Each of the conformations had two 
minimum energy structures, represented by ae1, ae2, 
ea1 and ea2 (Figure 3). The analysis of the data in Table 2 
shows that the conformers with the carbamate group in the 
axial position (ae) have lower energy than the conformers 
with the arylamine group in axial position (ea). These 
results agree with the values of the coupling constant 3JHH 
obtained from the 1H NMR spectra. In this case, values 
of 3JHH over 9.3 Hz were observed only for hydrogen H2, 
indicating that it is in axial position and, consequently, 
the arylamine group is in equatorial position.
The preference of conformer ae can also be explained by 
the steric repulsion between the individual substituents and 
the hydrogens in 1 and 3 arrangements. In the ae 
conformation, the atoms of the carbamate group (despite 
its volume being greater than that of the arylamine group) 
are relatively distant from the cyclohexane ring, which 
decreases the syn 1,3-diaxial interactions. In contrast, in the 
ea conformation, the arylamine group is close to the ring, 
causing a greater repulsion between the hydrogen in the 
amine group and the 1,3-diaxial hydrogens. These results 
are consistent with previous studies published on these 
compounds.34,35
The effect of hyperconjugative interactions on 
conformers ae and ea was assessed by means of NBO 
analysis, using B3LYP/6-311++G(d,p) theory level.
Table 3 shows the main interactions involving the 
substituent groups. When the carbamate group is in axial 
position (ae), a stabilizing orbital interaction occurs between 
σC2-H2’ → σ*C1-O, which has considerably more energy than 
the interaction between σC1-H1’ → σ*C2-N, which occurs when 
the arylamine group is in axial position (ea). This occurs 
because antibonding orbital σ*C1-O is a better electron 
acceptor than antibonding orbital σ*C2-N. The sum of the 
main hyperconjugative interactions of the substituent groups 
shows that they are more effective in the ae conformation, 
with a difference of about 1.50 kcal mol-1 in relation to the 
ea conformation. The conformational preference of the cis 
isomers can be assigned to both steric and electronic effects.
The molecular modeling calculations were also applied 
to the protonated form of the carbamates. The differences 
of energy between the conformers (Eee-Eea and Eae-Eea) were 
higher than 5.0 kcal mol-1, so ee and ae are the dominant 
conformers in the equilibrium.
Table 3. Hyperconjugative interactions obtained through NBO analysis for derivatives cis-2-arylaminocyclohexyl N,N-dimethylcarbamates
Conformer NBO donor NBO acceptor
E / (kcal mol-1)
5a 5b 5c
ae σC2-H2’ σ*C1-O 5.90 5.87 5.88
σC6-H6’ σ*C1-O 4.91 4.92 4.91
σC3-C4 σ*C2-N 2.71 2.68 2.71
σC1-C6 σ*C2-N 2.56 2.55 2.57
Total 16.08 16.02 16.07
ea σC1-H1’ σ*C2-N 3.98 3.95 3.98
σC3-H3’ σ*C2-N 4.27 4.21 4.29
σC5-C6 σ*C1-O 3.04 3.06 3.03
σC2-C3 σ*C1-O 3.29 3.33 3.29
Total 14.58 14.55 14.59
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Enzyme-inhibitor interactions
Molecular docking calculations were performed using 
the AutoDock 4.2.3 program implemented at the interface 
PyRx 0.936 to assess the enzyme-inhibitor interactions and 
propose a bonding model based on the experimental results. 
All the experimentally tested compounds were docked to 
both enzymes (AChE and BuChE) and their interactions 
were analyzed. Due to the similarity of the obtained results, 
the most active selective compound 2b’ was chosen as 
model in the present discussion. It is important to point 
out that only the most stable conformer of each isomer was 
used in the docking calculations.
Figure 4a shows the trans-2-(4-methoxyphenylamino)
cyclohexyl N,N-dimethylcarbamate hydrochloride 2b’ 
complexed with enzyme AChE. One can observe that the 
ligand is stabilized by residues of the catalytic anionic 
site Glu199 and Phe330 and by one of the residues of the 
anionic subsite, Gly118. There is a hydrogen bond between 
Hsd440 and the protonated amino group. Residues Trp84, 
Tyr334 and Tyr121 contribute to the stabilization through 
van der Waals interactions. The hydrolysis mechanism 
of acetylcholine involves mainly the catalytic triad 
residues (Ser200, His440 and Glu327). Upon analysis of 
the enzyme-substrate complex, one can observe that the 
carbamate group is distant from the catalytic triad residues, 
decreasing the possibility of the enzyme inhibition.
Figure 4b shows the ligand complexed with enzyme 
BuChE. In this case, one can observe that the carbamate 
group is close to the catalytic triad residues of the enzyme 
(Ser198, Hsd438 and Glu325), enabling the nucleophilic 
attack of the oxygen of Ser198 to the carbonyl of the 
carbamate group. It can also be observed that the arylamine 
group is stabilized by hydrogen bonds with Glu197, 
Gly116 and Ser198, and those residues Tyr128, Trp82 and 
Tyr440 contribute to stabilize the ligand through van der 
Waals interactions.
In general, the molecular docking results show that 
the assessed compounds are located in the active site of 
both enzymes, but in butyrylcholinesterase, the carbamate 
group is close to the catalytic triad residues, whereas in 
acetylcholinesterase this group is farther away. These 
results agree with the experimental data, which showed that 
the tested compounds are selective inhibitors of enzyme 
butyrylcholinesterase.
Conclusions
New selective inhibitors of enzyme BuChE may serve 
as biological investigative tools of its role in AD and 
its treatment. This study resulted in a series of new 
cholinesterase inhibitors, selective BuChE inhibitors 
(2a’-2c’, 5b’ and 5c’), and one non-selective AChE/BuChE 
inhibitor (5a’). The in vitro inhibition test by Ellman’s 
modified method showed that the cis-trans isomerism does 
not influence the activity of the compounds significantly, 
but that the presence of donor and acceptor substituents in 
the para position of the aromatic ring may either increase 
or decrease the activity of the compounds, depending on 
the series being analyzed.
According to the DFT (density functional theory) 
calculations, the trans carbamates presented diequatorial 
substitution as major conformers, which can be attributed to 
steric repulsion between the substituents and the hydrogens 
in 1 and 3 arrangements (syn 1,3-diaxial interactions). For 
the cis isomers, the most stable conformer is the one with 
the carbamate group in axial position and the arylamine 
group in equatorial position. In this case, the conformational 
preference is explained both by steric and electronic effects.
Figure 4. Active sites of enzymes (a) AChE and (b) BuChE complexed 
with trans-2-(4-methoxyphenylamino)cyclohexyl N,N-dimethylcarbamate 
hydrochloride 2b’.
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Molecular modeling studies attributed the selectivity 
of the compounds toward BuChE to the distance between 
the carbamoyl group and the catalytic site of the enzyme. 
In the BuChE, the carbamoyl group is oriented towards 
the catalytic triad, creating import interactions between 
the triad and the active site. In contrast, in AChE, the long 
distance between the carbamoyl group and the catalytic triad 
of enzyme makes difficult any interaction between them. 
Overall, these results indicate that the novel carbamate 
derivatives are interesting structures for the development 
of selective and more potent BuChE inhibitors.
Experimental
General experimental procedures
NMR spectra were acquired in a Varian Mercury 
Plus BB apparatus operating at 300.059 MHz for 1H and 
75.457 MHz for 13C. The spectra were recorded in 
20 mg cm-3 solutions of CDCl3, with a probe temperature 
of ca. 300 K and TMS (tetramethylsilane) as reference. 
Melting points were determined with a Micro-Química 
apparatus model MQAPF-301 and are uncorrected.
HRMS analyses were performed for new 2-arylamino-
cyclohexyl N,N-dimethylcarbamates. The compounds 
were dissolved in a solution of 50% (v/v) chromatographic 
grade acetonitrile (Tedia, Fairfield, OH, USA), 50% (v/v) 
deionized water and 0.1% formic acid. The solutions were 
infused directly and individually into the ESI (electrospray 
ionization) source by means of a syringe pump (Harvard 
Apparatus) at a flow rate of 10 μL min−1. ESI(+)-MS and 
tandem ESI(+)-MS/MS were acquired using a hybrid high-
resolution and high accuracy (5 μL L-1) MicrOTOF-Q II 
mass spectrometer (Bruker Daltonics) under the following 
conditions: capillary and cone voltages were set to +3500 and 
+40 V, respectively, with a de-solvation temperature of 
200 oC. For data acquisition and processing, Micro-TOF 
software (Bruker Daltonics) was used. The data were collected 
in the m/z range of 50-400 at the speed of two scans per s, 
providing the resolution of 50,000 (FWHM) at m/z 200.
Procedures for the synthesis and purification of all 
compounds are described in the Supplementary Information 
section.
Cholinesterase inhibition bioassay
The inhibitory activity of cholinesterases (AChE and 
BuChE) was evaluated in fresh human blood by Ellman’s 
modified spectrophotometric method.32 For measurement, 
10 mL of a 100 mmol L-1 phosphate buffer solution 
pH 8.0 and 10 μL of heparinized fresh blood were used. 
To determine the total amount of cholinesterases, 3.0 mL 
of solution (erythrocyte + plasma) were transferred to 
vials and 40 μL of tested compounds were preincubated 
with the enzymes for 10 min at 30 ºC before starting the 
reaction by adding of the substrate (acetylthiocholine 
iodide). Next, 50 μL of 10 mmol L-1 DTNB (Ellman’s 
reagent, Sigma-Aldrich Co.) solution and 20 μL of 
75 mmol L-1 acetylthiocholine iodide (Sigma-Aldrich Co.) 
solution were added. Enzyme activity was determined 
by measuring the absorbance at 412 nm for 5 min with a 
Shimadzu UV-1061PC apparatus. An inhibitor-free sample 
was used (100% enzyme activity) as a reference. Each 
compound was assayed at five concentrations in triplicate. 
The reaction rates were compared and the percent inhibition 
due to the presence of the tested compounds was calculated. 
The IC50 values were determined by spectrophotometric 
measurement of the effect of increasing compound 
concentrations on the enzyme activity.
To determine the plasma cholinesterase (BuChE), 
heparinized fresh blood was centrifuged at 2000 rpm for 
10 min for the sedimentation of red blood cells, and 20 μL 
of the supernatant (plasma) were added to 12 mL of a 
100 mmol L-1 phosphate buffer solution at pH 8.0. Amounts 
of 3.0 mL of this solution were transferred to vials and 
40 μL of test compounds were preincubated with the 
enzymes for 10 min at 30 ºC. Next, 25 μL of 10 mmol L-1 
DTNB solution and 20 μL of 75 mmol L-1 acetylthiocholine 
iodide solution were added. Enzyme activity was measured 
as for total cholinesterase.
Ligand modeling
The molecular modeling calculations were performed 
with Gaussian 03 package programs.33 Energy potential 
surfaces were obtained for all the compounds at theory 
level HF/6-31G to determine the position of lowest 
energy adopted by the groups in space. The lowest 
energy structures were optimized at a high level of theory 
[B3LYP/6-311++G(d,p)] and characterized as absolute 
minima by vibrational frequency calculations. NBO 
calculations (version 5.0) were performed to evaluate 
the hyperconjugative interactions using theory level 
B3LYP/6-311++G(d,p).
Molecular docking
Molecular docking studies were performed using the 
AutoDock 4.2.3 program implemented at the interface 
PyRx 0.9.36 The compounds under study were docked to 
1GQR crystallographic structures, AChE complexed with 
rivastigmine, and 1POM, BuChE complexed with choline 
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ions, selected from the Protein Data Bank (PDB). For each 
PDB file, molecules of water and other ligands (except the 
main ligands rivastigmine and choline ion) were removed. 
Redocking calculations were performed to validate the 
parameters that had been chosen. The compound structures 
were drawn and optimized with the Gaussian 09 program33 
as described in the Ligand Modeling section.
The docking calculations for the enzymes and compounds 
were performed by building a 50 × 50 × 50 Å box centered 
at coordinates x = 8.058, y = 64.887 and z = 61.330 for 
AChE and x = 132.478, y = 114.974 and z = 38.835 for 
BuChE with a grid space of 0.375 Å. The genetic algorithm 
(GA) was used as a standard protocol of 50 poses obtained for 
the ligand, an initial population of 150 random individuals, 
a maximum number of 2.5 × 105 energy evaluations and 
a maximum of 2.7 × 104 generations. The docked results 
within an RMSD (root mean square deviation) of 2.0 Å were 
clustered and the final results of each ligand were selected 
considering both the embedded empirical binding free energy 
evaluation and the clustering analysis.
The best results were submitted to energy minimization 
with the NAMD2 program.37 The force field adopted for 
proteins was CHARMM C35b2-C36a2, and for the ligands, 
they were generated in the same format by the SwissParam 
server.38 Energy minimization was simulated with the 
complexes immersed in a box with water measuring at least 
10 Å from the outermost surface of the protein. Either Na+ 
or Cl– counter ion was added in appropriate amounts to 
neutralize the charges of the system. The temperature and 
the pressure were adjusted to 300 K and 1 atm. After energy 
minimization, the protein-ligand complexes were redocked 
using the same docking parameters, which gave a maximum 
RMSD of 1.5 Å.
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(A) Preparation of trans-2-arylaminocyclohexanols 1a-1c1
In a two-necked flask equipped with a magnetic stirrer, 
51 mmol of appropriate arylamine (4.65 mL of aniline, 
6.3 g of p-anisidine or 4.8 mL of p-fluoraniline) and 
cyclohexene oxide (49 mmol) were consecutively added 
in water (100 mL) and the resulting mixture was left under 
vigorous stirring at 60 oC for 48 h. The mixture was basified 
with 5 mol L-1 NaOH until pH 10 and extracted with ethyl 
acetate (3 × 30 mL). The combined organic layers were 
dried over anhydrous Na2SO4. The solvent was evaporated 
and the product pure was isolated.
trans-2-Phenylaminocyclohexanol 1a: white solid; 
mp 58-59 oC; 50% yield.
trans-2-(4-Methoxyphenylamino)cyclohexanol 1b: 
brown solid; mp 67-68 oC; 80% yield.
trans-2-(4-Fluoropheyilamino)cyclohexanol 1c: white 
solid; mp 94-95 oC; 50% yield.
(B) Preparation of 2-bromocyclohexanone2
Cyclohexanone (19 mL, 180 mmol) and water (70 mL) 
were placed in a three-necked flask equipped with a stirrer 
and a dropping funnel. Bromine (9.5 mL, 180 mmol) 
was added dropwise to the stirred heterogeneous mixture 
during 1 h, and a water-ice bath (0-5 oC) was employed to 
cool the reaction. When addition was completed, stirring 
was continued until the reaction mixture was colorless 
(30-60 min). The mixture was extracted with ethyl ether 
(3 × 30 mL), the combined organic layers were dried over 
anhydrous Na2SO4. The filtrate was concentrated under 
reduced pressure (73 oC, 2 mmHg) to give the product 
(70% yield).
(C) Preparation of 2-arylaminocyclohexanones 3a-3c3
0.2 mol of the appropriate arylamine (18.2 mL of 
aniline, 24.6 g of p-anisidine or 19.0 mL of p-fluoroaniline), 
2-bromocyclohexanone (23 mL, 0.2 mmol), quinoline 
(2.4 mL, 0.02 mmol), 0.3 mol sodium carbonate (31.8 g, 
0.3 mmol) and 150 mL of 2-methoxyethanol were 
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added to a dry flask and the resulting reaction mixture 
was heated to reflux for 2 h. The reaction mixture was 
cooled to room temperature. The solid was removed by 
filtration and washed with chloroform. The filtrate was 
concentrated under reduced pressure to give crude product. 
Pure racemic α-arylaminocycloalkanone was obtained by 
recrystallization from anhydrous methanol.
2-(Phenylamino)cyclohexanone 3a: white solid; 
mp 81-82 oC; 30% yield.
2-(4-Methoxyphenylamino)cyclohexanone 3b: brown 
solid; mp 91-93 oC; 30% yield.
2-(4-Fluorophenylamino)cyclohexanone 3c: white solid; 
mp 75-76 oC; 30% yield.
(D) Preparation of cis-2-arylaminocyclohexanols 4a-4c4
4.55 mmol of the appropriate 2-arylaminocyclohexanone 
(0.9 g of 3a, 1.0 g of 3b and 1.0 g of 3c) were dissolved 
in dried THF (tetrahydrofuran, 25 mL) in a round-bottom 
flask under nitrogen atmosphere and magnetic stirring. 
After lowering the temperature to -78 °C, N-selectride 
(9.1 mL, 9.1 mmol) was added, and the reactor was kept 
under stirring for 4 h. The reaction mixture was allowed to 
attain room temperature, after which it was hydrolyzed with 
water (2.0 mL) and ethanol (5.0 mL). The organoborane 
was oxidized with 6.0 mol L-1 NaOH (4.0 mL) and 30% 
H2O2 (5.0 mL). The aqueous phase was than saturated with 
CaCO3 and extracted with ethyl ether. The two organic 
portions were joined, dried with MgSO4 and carried to a 
rotary evaporator where the solvent was removed.
cis-2-Phenylaminocyclohexanol 4a: white solid; 
mp 70-72 oC; 35% yield.
cis-2-(4-Methoxyphenylamino)cyclohexanol 4b: brown 
solid; mp 51-52 oC; 45% yield.
cis-2-(4-Fluorophenylamino)cyclohexanol 4c: white 
solid; mp 73-74 oC; 50% yield.
(E) Preparation of new cis- and trans-2-arylaminocyclohexyl 
N,N-dimethylcarbamates 2a, 2b, 5a and 5b5
23 mmol of the appropriate 2-arylaminocyclohexanol 
(4.4 g of 1a or 1b, 5.1 g of 4a or 4b) were dissolved in 
dried THF (30 mL) in a round-bottom flask under nitrogen 
atmosphere and magnetic stirring. Following metalic 
sodium (1.0 g, 45 mmol) addition, the resulting reaction 
mixture was heated to 80 oC for 8 h. After this time, 
dimethylcarbamyl chloride (3.1 mL, 34 mmol) was added 
and the reaction was heated to reflux for 15 h.
The reaction mixture was cooled to room temperature, 
added cold solution of sodium bicarbonate 1% (50 mL), 
and extracted with ethyl ether (3 × 30 mL) and cold water 
(2 × 20 mL). The organic layers were dried over anhydrous 
Na2SO4. The solvent was evaporated and the crude product 
was obtained. Compounds 2a and 5a were purified washing 
the obtained solid repeatedly with cold hexane. Pure 
compounds 2b and 5b were obtained by silica gel column 
chromatography (hexane/ether 8:2).
trans-2-(Phenylamino)cyclohexyl N,N-dimethylcarbamate 
2a
White solid; mp 72.9-73.5 °C; 50% yield; 1H NMR 
(300 MHz, CDCl3) d 1.16-1.30 (m, 1H, Ha6), 1.32-1.42 
(m, 2H, Ha4 and Ha5), 1.40-1.52 (m, 1H, Ha3), 1.68-1.91 
(m, 2H, He4 and He5), 1.94-2.06 (m, 1H, He3), 2.10-2.22 
(m, 1H, He6), 2.67 (s, 1H, CH3), 2.81 (s, 1H, CH3), 3.32 
(ddd, 1H, J 9.3, 9.3, 4.2 Hz, H2), 4.64 (ddd, 1H, J 9.3, 9.3, 
4.2 Hz, H1), 6.54-6.64 (m, 2H, H2’ and H6’), 6.58-6.66 
(m, 1H, H4’), 7.12 (ddd, 2H, J 8.7, 7.2, 4.2 Hz, H3’ and 
H5’); 13C NMR (75 MHz, CDCl3) d 24.3 (C5), 24.4 (C4), 
31.7 (C3), 32.2 (C6), 35.9 (CH3), 36.5 (CH3), 57.2 (C2), 
76.8 (C1), 113.1 (C2’ and C6’), 116.9 (C4’), 129.2 (C3’ 
and C5’), 148.2 (C1’), 157.0 (C=O); ESI-HRMS calcd. 
for C15H23N2O2 ([M + H]+): 263.1760; found: 263.1837.
trans-2-(4-Methoxyphenylamino)cyclohexyl N,N-dimethyl-
carbamate 2b
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Brown oil; 50% yield; 1H NMR (300 MHz, CDCl3) d 
1.17-1.28 (m, 1H, Ha6), 1.28-1.39 (m, 2H, Ha4 and Ha5), 
1.38-1.50 (m, 1H, Ha3), 1.60-1.76 (m, 2H, He4 and He5), 
1.94-2.04 (m, 1H, He3), 2.07-2.18 (m, 1H, He6), 2.67 (s, 
1H, CH3), 2.82 (s, 1H, CH3), 3.28 (ddd, 1H, J 9.3, 9.3, 4.2 
Hz, H2), 3.72 (s, 1H, OCH3), 4.62 (ddd, 1H, J 9.3, 9.3, 
4.2 Hz, H1), 6.57 (d, 2H, J 9.0 Hz, H2’ and H6’), 6.73 (d, 
2H, J 9.0 Hz, H3’ and H5’); 13C NMR (75 MHz, CDCl3) 
d 24.2 (C5), 24.4 (C4), 31.5 (C3), 32.3 (C6), 35.8 (CH3), 
36.4 (CH3), 55.9 (OCH3), 58.1 (C2), 76.9 (C1), 114.5 (C2’ 
and C6’), 114.8 (C3’ and C5’), 142.5 (C1’), 151.8 (C4’), 
156.9 (C=O); ESI-HRMS calcd. for C16H25N2O3 ([M + H]+): 
293.1865; found: 293.1946.
cis-2-(Phenylamino)cyclohexyl N,N-dimethylcarbamate 5a
White solid; mp 68.1-70.0 °C; 39% yield; 1H NMR 
(300 MHz, CDCl3) d 1.34-1.44 (m, 1H, Ha4), 1.44-1.58 (m, 
2H, Ha5 and He5), 1.50-1.62 (m, 1H, Ha6), 1.52-1.66 (m, 
1H, Ha3), 1.69-1.77 (m, 1H, He4), 1.85-1.94 (m, 1H, He3), 
1.94-2.06 (m, 1H, He6), 2.91 (s, 2H, CH3), 3.50 (ddd, 1H, 
J 9.9, 3.3, 3.3 Hz, H2), 5.00-5.06 (m, 1H, H1), 6.55-6.64 
(m, 2H, H2’ and H6’), 6.62-6.70 (m, 1H, H4’), 7,14 (ddd, 
2H J 6.9, 6.9, 1.8 Hz, H3’ and H5’); 13C NMR (75 MHz, 
CDCl3) d 21.0 (C5), 23.9 (C4), 28.3 (C3), 29.6 (C6), 36.1 
(CH3), 36.6 (CH3), 53.6 (C2), 73.3 (C1), 113.4 (C2’ and 
C6’), 117.4 (C4’), 129.4 (C3’ and C5’), 147.3 (C1’), 156.4 
(C=O); ESI-HRMS calcd. for C15H23N2O2 ([M + H]+): 
263.1760; found: 263.1842.
cis-2-(4-Methoxyphenylamino)cyclohexyl N,N-dimethyl-
carbamate 5b
Brown oil; 23% yield; 1H NMR (300 MHz, CDCl3) 
d 1.28-1.42 (m, 1H, Ha4), 1.34-1.42 (m, 1H, Ha5), 1.44-1.56 
(m, 2H, He5 and Ha6), 1.47-1.62 (m, 1H, Ha3), 1.64-1.76 
(m, 1H, He4), 1.80-1.92 (m, 1H, He3), 1.92-2.06 (m, 1H, 
He6), 2.90 (s, 2H, CH3), 3.38 (ddd, 1H, J 9.6, 3.3, 3.3 Hz, 
H2), 3.72 (s, 1H, OCH3), 4.96-5.04 (m, 1H, H1), 6.57 (d, 
2H, J 9.3 Hz, H3’ and H5’), 6.75 (d, 2H, J 9.0 Hz, H2’ 
and H6’); 13C NMR (75 MHz, CDCl3) d 20.8 (C5), 23.9 
(C4), 28.4 (C3), 29.5 (C6), 36.0 (CH3), 36.4 (CH3), 54.7 
(C2), 55.8 (OCH3), 73.0 (C1), 115.0 (C2’ and C6’), 115.1 
(C3’ and C5’), 141.3 (C1’), 152.1 (C4’), 156.1 (C=O); 
ESI-HRMS calcd. for C16H25N2O3 ([M + H]+): 293.1865; 
found: 293.1944.
(F) Preparation of cis- and trans-2-(4-fluorophenylamino)
cyclohexyl N,N-dimethylcarbamate 2c and 5c
12 mmol of the appropriate 2-arylaminocyclohexanol 
were dissolved in dried THF (30 mL) in a round-bottom flask 
under nitrogen atmosphere and magnetic stirring. Following, 
sodium hydride (0.6 g, 24 mmol) was added and the resulting 
reaction mixture was heated to 80 oC for 8 h. After this time, 
dimethylcarbamyl chloride (3.1 mL, 34 mmol) was added 
and the reaction was heated to reflux for 15 h. The reaction 
mixture was cooled to room temperature, added cold solution 
of sodium bicarbonate 1% (50 mL) and extracted with ethyl 
ether (3 × 30 mL) and cold water (2 × 20 mL). The organic 
layers were dried over anhydrous Na2SO4. The solvent 
was evaporated and the crude product was obtained. Pure 
compounds 2b and 5b were obtained by silica gel column 
chromatography (hexane/ether 8:2).
trans-2-(4-Fluorophenylamino)cyclohexyl N,N-dimethyl-
carbamate 2c
White solid; mp 54.5-56.4 °C; 35% yield; 1H NMR 
(300 MHz, CDCl3) d 1.19-1.29 (m, 1H, Ha6), 1.29-1.40 (m, 
2H, Ha4 and Ha5), 1.41-1.52 (m, 1H, Ha3), 1.67-1.81 (m, 
2H, He4 and He5), 1.96-2.05 (m, 1H, He3), 2.09-2.19 (m, 
1H, He6), 2.67 (s, 1H, CH3), 2.82 (s, 1H, CH3), 3.25 (ddd, 
1H, J 9.6, 9.6, 3.9 Hz, H2), 4.63 (ddd, 1H, J 9.3; 9.3; 4.0 Hz, 
H1), 6.49-6.56 (m, 2H, H2’ and H6’), 6.79-6.87 (m, 2H, 
H3’ and H5’); 13C NMR (75 MHz, CDCl3) d 24.3 (C5), 24.5 
(C4), 31.7 (C3), 32.3 (C6), 35.9 (CH3), 36.5 (CH3), 58.0 
(C2), 76.9 (C1), 114.0 (C2’ and C6’), 115.5 (C3’ and C5’), 
Molecular Modeling and Anticholinesterasic Activity of Novel 2-Arylaminocyclohexyl N,N-Dimethylcarbamates J. Braz. Chem. Soc.S4
144.6 (C1’), 155.6 (C4’), 156.9 (C=O); ESI-HRMS calcd. 
for C15H22FN2O2 ([M + H]+): 281.1665; found: 281.1741.
cis-2-(4-Fluorophenylamino)cyclohexyl N,N-dimethyl-
carbamate 5c
White solid; mp 66.4-67.5 oC; 45% yield; 1H NMR 
(300 MHz, CDCl3) d 1.30-1.40 (m, 1H, Ha4), 1.42-1.52 
(m, 2H, He4 and Ha5), 1.46-1.55 (m, 1H, Ha6), 1.46-1.58 
(m, 1H, Ha3), 1.64-1.74 (m, 1H, He5), 1.78-1.88 (m, 1H, 
He3), 1.90-2.02 (m, 1H, He6), 2.88 (s, 2H, CH3), 3.38 
(ddd, 1H, J 9.6;3.3;3.3 Hz, H2), 4.94-5.02 (m, 1H, H1), 
6.44-6.52 (m, 2H, H2’ and H6’), 6.76-6.87 (m, 2H, H3’ 
and H5’); 13C NMR (75 MHz, CDCl3) d 20.7 (C5), 23.8 
(C4), 28.1 (C3), 29.4 (C6), 35.8 (CH3), 36.3 (CH3), 54.2 
(C2), 72.7 (C1), 114.2 (C2’ and C6’), 115.5 (C3’ and C5’), 
143.5 (C1’), 155.6 (C4’), 156.0 (C=O); ESI-HRMS calcd. 
for C15H22FN2O2 ([M + H]+): 281.1665; found: 281.1847.
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(G) NMR spectra for new cis- and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates
Figure S1. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of trans-2-(phenylamino)cyclohexyl N,N-dimethylcarbamate 2a.
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Figure S2. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of trans-2-(4-methoxyphenylamino)cyclohexyl N,N-dimethylcarbamate 2b.
Figure S3. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of trans-2-(4-fluorophenylamino)cyclohexyl N,N-dimethylcarbamate 2c.
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Figure S4. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of cis-2-(phenylamino)cyclohexyl N,N-dimethylcarbamate 5a.
Figure S5. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of cis-2-(4-methoxyphenylamino)cyclohexyl N,N-dimethylcarbamate 5b.
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Figure S6. 1H NMR (CDCl3, 300 MHz) and 13C NMR (CDCl3, 75 MHz) spectra of cis-2-(4-fluorophenylamino)cyclohexyl N,N-dimethylcarbamate 5c.
Figure S7. ESI-HRMS spectra of trans-2-(phenylamino)cyclohexyl N,N-dimethylcarbamate 2a.
Figure S8. ESI-HRMS spectra of trans-2-(4-methoxyphenylamino)cyclohexyl N,N-dimethylcarbamate 2b.
(H) ESI-HRMS spectra for new cis- and trans-2-arylaminocyclohexyl N,N-dimethylcarbamates
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Figure S9. ESI-HRMS spectra of trans-2-(4-fluorophenylamino)cyclohexyl N,N-dimethylcarbamate 2c.
Figure S10. ESI-HRMS spectra of cis-2-(phenylamino)cyclohexyl N,N-dimethylcarbamate 5a.
Figure S11. ESI-HRMS spectra of cis-2-(4-methoxyphenylamino)cyclohexyl N,N-dimethylcarbamate 5b.
Figure S12. ESI-HRMS spectra of cis-2-(4-fluorophenylamino)cyclohexyl N,N-dimethylcarbamate 5c.
